Antipsychotic polypharmacy (APP) has become prevalent

over the years, but several concerns have been raised

over APP. Accumulating evidence suggests that

aripiprazole long-acting injectable (LAI) may reduce the

rate of APP, but the association remains speculative. This

retrospective observational study included 127 patients

with psychosis and observed them for 1.8 ± 1.3 years, up

to 4 years. Prescription data of antipsychotics (APs), mood

stabilisers, benzodiazepines, and anti-extrapyramidal

side effect medications were obtained at baseline and

the last observation. Daily chlorpromazine equivalent

(CPZ) dose of APs decreased from 124.40 ± 235.35 mg

to 77.95 ± 210.36 mg (P = 0.027). The daily dose of

anticholinergics and beta-blockers also significantly

decreased after introducing aripiprazole LAI. Among the

patients having APP, the number of concurrent APs along

with daily CPZ dose of APs decreased after initiation

of aripiprazole LAI from 1.28 ± 0.62 to 0.85 ± 0.73 (P <

0.001) and 298.33 ± 308.70 mg to 155.43 ± 280.53 mg (P

= 0.004), respectively. Treatment with aripiprazole LAI for